Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis

被引:0
|
作者
Yang Jiao
Yan Lu
Xiao-ying Li
机构
[1] Shanghai Institute of Endocrinology and Metabolism,Department of Endocrine and Metabolic Diseases
[2] Shanghai Clinical Center for Endocrine and Metabolic Diseases,The Key Laboratory of Endocrine Tumors and the Division of Endocrine and Metabolic Diseases
[3] Ruijin Hospital,undefined
[4] Shanghai Jiao Tong University School of Medicine,undefined
[5] E-Institute of Shanghai Universities,undefined
来源
Acta Pharmacologica Sinica | 2015年 / 36卷
关键词
farnesoid X receptor; non-alcoholic fatty liver disease; liver; triglyceride metabolism; glucose metabolism; drug discovery;
D O I
暂无
中图分类号
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is characterized by the aberrant accumulation of triglycerides in hepatocytes in the absence of significant alcohol consumption, viral infection or other specific causes of liver disease. NAFLD has become a burgeoning health problem both worldwide and in China, but its pathogenesis remains poorly understood. Farnesoid X receptor (FXR), a member of the nuclear receptor (NR) superfamily, has been demonstrated to be the primary sensor for endogenous bile acids, and play a crucial role in hepatic triglyceride homeostasis. Deciphering the synergistic contributions of FXR to triglyceride metabolism is critical for discovering therapeutic agents in the treatment of NAFLD and hypertriglyceridemia.
引用
收藏
页码:44 / 50
页数:6
相关论文
共 50 条
  • [1] Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis
    Jiao, Yang
    Lu, Yan
    Li, Xiao-ying
    ACTA PHARMACOLOGICA SINICA, 2015, 36 (01) : 44 - 50
  • [2] The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
    Rausch, Magdalena
    Samodelov, Sophia L.
    Visentin, Michele
    Kullak-Ublick, Gerd A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [3] Effect of simvastatin on the expression of farnesoid X receptor in diabetic animal models of altered glucose homeostasis
    Wang Lulu
    Huang Xianping
    Hu Su
    Ma Xiaoli
    Wang Shaolian
    Pang Shuguang
    CHINESE MEDICAL JOURNAL, 2014, 127 (02) : 218 - 224
  • [4] Farnesoid X receptor: An important factor in blood glucose regulation
    Hou, Yangfeng
    Fan, Wenjing
    Yang, Wenling
    Samdani, Abdul Qadir
    Jackson, Ampadu Okyere
    Qu, Shunlin
    CLINICA CHIMICA ACTA, 2019, 495 : 29 - 34
  • [5] Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
    Zhang, Limin
    Xie, Cen
    Nichols, Robert G.
    Chan, Siu H. J.
    Jiang, Changtao
    Hao, Ruixin
    Smith, Philip B.
    Cai, Jingwei
    Simons, Margaret N.
    Hatzakis, Emmanuel
    Maranas, Costas D.
    Gonzalez, Frank J.
    Patterson, Andrew D.
    MSYSTEMS, 2016, 1 (05)
  • [6] Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
    Li, Hong
    Shen, Jing
    Wu, Tong
    Kuang, Jiangying
    Liu, Qinhui
    Cheng, Shihai
    Pu, Shiyun
    Chen, Lei
    Li, Rui
    Li, Yanping
    Zou, Min
    Zhang, Zhiyong
    Jiang, Wei
    Qu, Aijuan
    He, Jinhan
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [7] Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand
    Takahashi, Miki
    Kanayama, Tomohiko
    Yashiro, Takuya
    Kondo, Hidehiko
    Murase, Takatoshi
    Hase, Tadashi
    Tokimitsu, Ichiro
    Nishikawa, Jun-ichi
    Sato, Ryuichiro
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 372 (03) : 395 - 399
  • [8] Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease
    Xi, Yingfei
    Li, Hongshan
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [9] Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor
    Duan, Xingping
    Meng, Qiang
    Wang, Changyuan
    Liu, Zhihao
    Liu, Qi
    Sun, Huijun
    Sun, Pengyuan
    Yang, Xiaobo
    Huo, Xiaokui
    Peng, Jinyong
    Liu, Kexin
    PHYTOMEDICINE, 2017, 25 : 83 - 92
  • [10] Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling
    Gu, Ming
    Zhang, Shiying
    Zhao, Yuanyuan
    Huang, Jinwen
    Wang, Yahui
    Li, Yin
    Fan, Shengjie
    Yang, Li
    Ji, Guang
    Tong, Qingchun
    Huang, Cheng
    PHARMACOLOGICAL RESEARCH, 2017, 121 : 22 - 32